FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™,
reported today its fiscal 2018 results.
FONAR’s primary source of income and growth is
attributable to its wholly-owned diagnostic imaging management
subsidiary, Health Management Company of America (HMCA). In 2009
FONAR managed 9 MRI facilities and had completed approximately
29,000 MRI scans. In 2010, Timothy Damadian, the Company’s current
President and CEO, re-joined the Company and initiated a business
plan aimed at growing HMCA by increasing scan volume at existing
HMCA-managed facilities, establishing de novo centers, and making
key acquisitions. With FONAR management’s enthusiastic endorsement
of his plan, Mr. Damadian assembled an experienced management team
that, under his leadership, has since faithfully executed the plan,
thereby delivering consistent and unprecedented profitability for
FONAR shareholders. Today, HMCA manages 26 diagnostic imaging
centers, 19 in New York and 7 in Florida, collectively equipped
with 34 MRI scanners. The imaging centers completed 176,000 MRI
scans in fiscal 2018, as compared to 164,000 the previous fiscal
year.
FONAR sold and installed the world’s first
commercial MRI scanner in 1980, making it the first company in the
now multi-billion-dollar MRI industry. FONAR’s flagship product is
the FONAR UPRIGHT® Multi-Position™ MRI, aka Stand-Up® MRI. It is
the only whole-body MRI that performs Position™ Imaging (pMRI™),
which allows patients to be scanned in numerous weight-bearing
positions, including standing, sitting, in flexion and extension,
as well as in the conventional lie-down position.
Financial Discussion:
Net revenues increased by 4% to $81.5 million
for the fiscal year ended June 30, 2018, as compared to $78.0
million for the fiscal year ended June 30, 2017.
For the year ended June 30, 2018, the revenues
from the management of the diagnostic imaging center segment,
consisting of patient and management and other fee revenue, and
less the provision for bad debt for patient revenue, increased by
7% to $71.7 million as compared to $66.8 million one year
earlier.
Income from operations increased by 3% to $19.7
million for the fiscal year ended June 30, 2018, as compared to
$19.1 million for the fiscal year ended June 30, 2017.
Net Income increased by 7% to $25.5 million, for
the fiscal year ended June 30, 2018, as compared to $23.7 million
for the fiscal year ended June 30, 2017. Net income for the year
ended June 30, 2018, reflects income tax benefits associated with
changes to the net deferred income tax assets of $4.9 million and
also the benefits associated with an AMT Carryforward Tax Credit of
$1.2 million, available as a cash refund. These income tax benefits
were precipitated in combination by both the Tax Cuts and Jobs Act
enacted in December 2017, which decreased the corporate income tax
rate from 35% to 21%, effective January 1, 2018, and the continued
strength of the business.
Basic net income per common share available to
common shareholders increased by 6% to $3.16 for the fiscal year
ended June 30, 2018, as compared to $2.98 for the fiscal year ended
June 30, 2017.
Diluted net income per common share available to
common shareholders increased by 6% to $3.10, compared to $2.92 for
the fiscal year ended June 30, 2017.
Total Costs and Expenses for the fiscal year
ending June 30, 2018 increased by 5% to $61.8 million, as compared
to $58.9 million for the fiscal year ended June 30, 2017.
At June 30, 2018, total assets increased by 20%
to $118.3 million, as compared to $98.8 million at June 30,
2017.
At June 30, 2018, total current assets increased
by 26% to $67.1 million, as compared to $53.4 million at June 30,
2017.
At June 30, 2018, total liabilities increased by
1% to $16.1 million, as compared to $15.9 million at June 30,
2017.
At June 30, 2018, total current liabilities
decreased by 2% to $14.6 million, as compared to $14.2 million at
June 30, 2017.
At June 30, 2018, total cash and cash
equivalents increased by 94% to $19.6 million, as compared to $10.1
million at June 30, 2017.
At June 30, 2018, working capital increased by
34% to $52.5 million, as compared to $39.2 million at June 30,
2017.
At June 30, 2018, FONAR Stockholder’s Equity
increased by 27% to $98.7 million, as compared to $77.4 million at
June 30, 2017.
Significant Events
On September 3, 2018, Dr. Damadian’s
presentation of ‘The First MRI Scan’ was featured on the BBC
(British Broadcasting Corporation) radio program, Witness. During
the nine-minute broadcast to a BBC World Service radio network
audience of more than 300 million listeners world-wide, Dr.
Damadian relived the excitement of the moment when he conducted the
world’s first MRI scan. “Well, we put Larry (Minkoff) in, we got a
signal immediately from his heart, and I said, “Holy smokes. It’s
actually going to work!’” The BBC broadcast of this pioneering
episode in MRI can be heard online at:
https://www.bbc.co.uk/programmes/w3cswsj4
First quarter Fiscal 2018 was the first complete
quarter in which FONAR stock was included in the Russell 3000®
Index, having joined the index effective June 26, 2017. The Company
has since seen an increase in related index funds and ETFs
(Exchange Traded Funds), mutual funds, and institutional owners.
Currently, institutional ownership of outstanding FONAR Common
Stock is over 50%.
In October, 2017, HMCA added a second Stand-Up®
MRI in the Bronx, NY, in order to meet the demands of patients and
referring physicians for FONAR technology.
Also, in December, 2017, the Tax Cuts and Jobs
Act was signed into law, making numerous changes to the Internal
Revenue Code. Among them is the reduction of the U.S. corporate
income tax rate to 21%, effective January 1, 2018. Because the Act
took effect midway through the Company’s tax year, the Company will
have a U.S. statutory income tax rate of 27.7% for fiscal 2018 and
a statutory income tax rate of 21% for all subsequent fiscal
years.
Management Discussion
President and CEO, Timothy R. Damadian, said,
“As of June 30, our cash and cash equivalents figure stood at $19.6
million, nearly double what is was a year earlier. Together with a
34% increase in working capital and consistent revenue growth, we
are well positioned to pursue new business opportunities consistent
with our growth strategy – opportunities that will enable us to
maintain our positive earnings trajectory into fiscal 2019.
“Of course, I am pleased with our Income from
Operations and Net Income. We remain committed to controlling
costs. The Company’s Selling, General, and Administrative
(SG&A) costs decreased by $1.3 million, or 7%,
year-over-year.”
Mr. Damadian concluded, “Thanks to the enormous
appeal of the UPRIGHT® MRI (also known as the Stand-Up® MRI) among
both patients and physicians, and thanks to our experienced and
highly competent management team, we continue to thrive.”
Chairman of the Board, Raymond V. Damadian,
M.D., said, “We continue to explore the impact of our new
works-in-progress technology for visualizing and quantifying the
flow of cerebrospinal fluid (CSF) circulating throughout the brain
and vertebral column while the patient is scanned in the Upright
position.”
Dr. Damadian added, “The Company was recently
issued a patent covering the use of the FONAR UPRIGHT®
Multi-Position™ MRI to diagnose patients with Multiple Sclerosis
(MS). The patent is based on a discovery FONAR had announced on
November 2, 2011. We are hopeful that this research will help to
lead to a new understanding of the role of CSF on brain diseases,
like MS.”
Dr. Damadian concluded, “It has been 47 years
since we announced the discovery that birthed the MRI industry.*
We’ve had the privilege and joy of witnessing its marvelous growth
from infancy. Today there are tens of millions of MRI scans
performed each year worldwide in what has become a
multi-billion-dollar industry. After all these years, FONAR is
finally reaping the rewards, and we’re certainly very thankful for
it.”
* In 1971, Dr. Damadian’s paper in Science
contained the two key discoveries that remain fundamental to the
operation of every MRI scanner ever made: 1) his discovery that the
relaxation times of cancerous tissues, are markedly prolonged
relative to those of healthy tissues and 2) his discovery that
there are also marked differences in relaxation times across the
full spectrum of healthy tissue types.
About FONAR
FONAR, the Inventor of MR Scanning™ is the
first, oldest and most experienced MRI company in the industry.
Incorporated in 1978, FONAR, which is located in Melville, New
York, introduced the world’s first commercial MRI in 1980, and went
public in 1981. The company’s signature product is the FONAR
UPRIGHT® Multi-Position™ MRI (also known as the Stand-Up® MRI), the
only whole-body MRI that performs Position™ Imaging (pMRI™),
allowing it to scan patients in numerous weight-bearing positions,
i.e. standing, sitting, in flexion and extension, as well as in the
conventional lie-down position.
The FONAR UPRIGHT® MRI often detects patient
problems that other MRI scanners cannot because they are lie-down,
“weightless-only” scanners. The patient-friendly UPRIGHT® MRI has a
near-zero patient claustrophobic rejection rate. As a FONAR
customer states, “If the patient is claustrophobic in this scanner,
they’ll be claustrophobic in my parking lot.” Approximately 85% of
patients are scanned sitting while watching TV.
FONAR has new works-in-progress technology for
visualizing and quantifying the cerebral hydraulics of the central
nervous system, the flow of cerebrospinal fluid (CSF), which
circulates throughout the brain and vertebral column at the rate of
32 quarts per day. This imaging and quantifying of the dynamics of
this vital life-sustaining physiology of the body’s neurologic
system has been made possible first by FONAR’s introduction of the
MRI and now by this latest works-in-progress method for quantifying
CSF in all the normal positions of the body, particularly in its
upright flow against gravity. Patients with whiplash or other neck
injuries are among those who will benefit from this new
understanding.
FONAR’s substantial list of patents includes
recent patents for its technology enabling full weight-bearing MRI
imaging of all the gravity sensitive regions of the human anatomy,
especially the brain, extremities and spine. It includes its newest
technology for measuring the Upright cerebral hydraulics of the
central nervous system. FONAR’s UPRIGHT® Multi-Position™ MRI is the
only scanner licensed under these patents.
UPRIGHT® and STAND-UP® are registered trademarks
and The Inventor of MR Scanning™, Full Range of Motion™,
Multi-Position™, Upright Radiology™, The Proof is in the Picture™,
True Flow™, pMRI™, Spondylography™, Dynamic™, Spondylometry™, CSP™,
and Landscape™, are trademarks of FONAR Corporation.
This release may include forward-looking
statements from the company that may or may not materialize.
Additional information on factors that could potentially affect the
company's financial results may be found in the company's filings
with the Securities and Exchange Commission.
|
CONSOLIDATED BALANCE SHEETS |
|
ASSETS |
|
|
|
June 30, |
|
|
2018 |
|
2017 |
Current Assets: |
|
|
|
|
Cash
and cash equivalents |
|
$19,663,742 |
|
$10,139,621 |
Accounts receivable – net of allowances for doubtful
accounts of $190,244 at June 30, 2018 and 2017 |
|
3,813,756 |
|
4,321,760 |
Medical receivables – net of allowances for doubtful
accounts of $22,727,698 and $19,853,318 at June
30, 2018 and 2017, respectively |
|
13,350,772 |
|
11,744,704 |
Management and other fees receivable – net of
allowances for doubtful accounts of $10,983,022 and
$12,859,750 at June 30, 2018 and 2017,
respectively |
|
21,863,431 |
|
18,593,894 |
Management and other fees receivable – related party
medical practices – net of allowances for doubtful
accounts of $1,711,385 and $582,001 at June 30,
2018 and 2017, respectively |
|
5,535,096 |
|
4,959,598 |
Costs
and estimated earnings in excess of billings on
uncompleted contracts |
|
86,638 |
|
736,061 |
Inventories |
|
1,431,380 |
|
1,624,262 |
Prepaid expenses and other current assets |
|
1,349,907 |
|
1,293,806 |
|
|
|
|
|
Total
Current Assets |
|
67,064,542 |
|
53,413,706 |
Income taxes receivable |
|
1,200,000 |
|
- |
Deferred income tax asset |
|
22,689,011 |
|
17,861,777 |
Property and Equipment – Net |
|
16,492,278 |
|
16,462,504 |
Goodwill |
|
3,985,397 |
|
3,927,123 |
Other
Intangible Assets – Net |
|
5,601,656 |
|
6,644,504 |
Other
Assets |
|
1,278,061 |
|
452,952 |
Total
Assets |
|
$118,310,945 |
|
$98,762,566 |
CONSOLIDATED BALANCE SHEETS |
|
LIABILITIES |
|
|
|
June 30, |
|
|
2018 |
|
2017 |
Current Liabilities: |
|
|
|
|
Current portion of long-term debt and capital leases |
|
$38,332 |
|
$180,090 |
Accounts payable |
|
1,300,250 |
|
1,423,217 |
Other
current liabilities |
|
8,177,995 |
|
7,203,278 |
Unearned revenue on service contracts |
|
4,191,930 |
|
4,641,534 |
Customer deposits |
|
858,195 |
|
787,884 |
Total
Current Liabilities |
|
14,566,702 |
|
14,236,003 |
|
|
|
|
|
Long-Term Liabilities: |
|
|
|
|
Deferred income tax liability |
|
239,011 |
|
331,527 |
Due
to related party medical practices |
|
227,543 |
|
227,543 |
Long-term debt and capital leases, less current portion |
|
306,035 |
|
336,761 |
Other
liabilities |
|
737,183 |
|
720,779 |
Total
Long-Term Liabilities |
|
1,509,772 |
|
1,616,610 |
Total
Liabilities |
|
16,076,474 |
|
15,852,613 |
CONSOLIDATED BALANCE SHEETS |
|
STOCKHOLDERS EQUITY |
|
|
|
June 30, |
|
|
2018 |
|
2017 |
Stockholders' Equity: |
|
|
|
|
Class
A non-voting preferred stock $.0001 par value;
453,000 shares authorized at June 30, 2018 and
2017, 313,438 issued and outstanding at June 30,
2018 and 2017 |
|
$31 |
|
|
$31 |
|
Preferred stock $.001 par value; 567,000 shares
authorized at June 30, 2018 and 2017, issued and
outstanding – none |
|
– |
|
|
– |
|
Common stock $.0001 par value; 8,500,000 shares
authorized at June 30, 2018 and 2017, 6,299,154
issued at June 30, 2018 and 2017, 6,287,511
outstanding at June 30, 2018 and 2017 |
|
630 |
|
|
630 |
|
Class
B convertible common stock (10 votes per share)
$.0001 par value; 227,000 shares authorized at June
30, 2018 and 2017, 146 issued and outstanding at
June 30, 2018 and 2017 |
|
– |
|
|
– |
|
Class
C common stock (25 votes per share) $.0001 par
value; 567,000 shares authorized at June 30, 2018
and 2017, 382,513 issued and outstanding at June
30, 2018 and 2017 |
|
38 |
|
|
38 |
|
Paid-in capital in excess of par value |
|
179,131,780 |
|
|
179,131,780 |
|
Accumulated deficit |
|
(79,772,587 |
) |
|
(101,003,389 |
) |
Notes
receivable from employee stockholders |
|
(9,213 |
) |
|
(16,546 |
) |
Treasury stock, at cost – 11,643 shares of common stock
at June 30, 2018 and 2017 |
|
(675,390 |
) |
|
(675,390 |
) |
Total
Fonar Corporation’s Stockholders’ Equity |
|
98,675,289 |
|
|
77,437,154 |
|
Noncontrolling interests |
|
3,559,182 |
|
|
5,472,799 |
|
Total
Stockholders' Equity |
|
102,234,471 |
|
|
82,909,953 |
|
Total
Liabilities and Stockholders' Equity |
|
$118,310,945 |
|
|
$98,762,566 |
|
CONSOLIDATED STATEMENTS OF INCOME |
|
|
|
For the Years Ended June 30, |
|
|
2018 |
|
2017 |
|
2016 |
Revenues |
|
|
|
|
|
|
Product sales – net |
|
$602,541 |
|
|
$1,572,148 |
|
|
$1,276,882 |
|
Service and repair fees – net |
|
9,124,728 |
|
|
9,537,040 |
|
|
9,396,736 |
|
Service and repair fees – related parties – net |
|
110,000 |
|
|
110,000 |
|
|
110,000 |
|
Patient fee revenue, net of contractual allowances and
discounts |
|
39,165,413 |
|
|
36,400,600 |
|
|
32,985,809 |
|
Provision for bad debts for patient fee |
|
(17,896,528 |
) |
|
(16,171,434 |
) |
|
(14,539,786 |
) |
Management and other fees – net |
|
41,422,958 |
|
|
38,361,514 |
|
|
36,633,230 |
|
Management and other fees – related party medical practices –
net |
|
8,986,882 |
|
|
8,226,718 |
|
|
7,505,339 |
|
Total
Revenues – Net |
|
81,515,994 |
|
|
78,036,586 |
|
|
73,368,210 |
|
Costs
and Expenses |
|
|
|
|
|
|
Costs
related to product sales |
|
751,221 |
|
|
931,501 |
|
|
1,254,328 |
|
Costs
related to service and repair fees |
|
3,212,527 |
|
|
2,996,736 |
|
|
2,148,143 |
|
Costs
related to service and repair fees – related parties |
|
38,728 |
|
|
34,564 |
|
|
25,147 |
|
Costs
related to patient fee revenue |
|
10,256,951 |
|
|
8,987,673 |
|
|
9,418,935 |
|
Costs
related to management and other fees |
|
22,778,202 |
|
|
20,828,581 |
|
|
21,949,583 |
|
Costs
related to management and other fees – related party medical
practices |
|
4,913,141 |
|
|
4,273,370 |
|
|
4,074,762 |
|
Research and development |
|
1,755,747 |
|
|
1,480,670 |
|
|
1,631,846 |
|
Selling, general and administrative, inclusive of compensatory
element of stock issuances of $0, $2,397,276 and
$2,006 for the years ended June 30, 2018, 2017
and 2016, respectively |
|
18,125,266 |
|
|
19,407,411 |
|
|
18,509,850 |
|
Total
Costs and Expenses |
|
61,831,783 |
|
|
58,940,506 |
|
|
59,012,594 |
|
Income from Operations |
|
19,684,211 |
|
|
19,096,080 |
|
|
14,355,616 |
|
Other
Income and (Expenses): |
|
|
|
|
|
|
Interest expense |
|
(160,074 |
) |
|
28,299 |
|
|
(262,193 |
) |
Investment income |
|
262,569 |
|
|
193,141 |
|
|
224,263 |
|
Other
(expense) income – net |
|
(4,271 |
) |
|
(1,156 |
) |
|
190,560 |
|
Income before benefit for income taxes and noncontrolling
interests |
|
19,782,435 |
|
|
19,316,364 |
|
|
14,508,246 |
|
Benefit for Income Taxes |
|
5,669,750 |
|
|
4,362,434 |
|
|
4,287,271 |
|
Net
Income |
|
$25,452,185 |
|
|
$23,678,798 |
|
|
$18,795,517 |
|
Net
Income – Noncontrolling Interests |
|
(4,221,383 |
) |
|
(4,058,177 |
) |
|
(3,070,892 |
) |
Net
Income – Attributable to FONAR |
|
$21,230,802 |
|
|
$19,620,621 |
|
|
$15,724,625 |
|
CONSOLIDATED STATEMENTS OF INCOME (Continued) |
|
|
|
For the Years Ended June 30, |
|
|
2018 |
|
2017 |
|
2016 |
Net
Income Available to Common Stockholders |
|
$19,899,823 |
|
$18,390,586 |
|
$14,702,834 |
Net
Income Available to Class A Non- Voting
Preferred Stockholders |
|
$992,005 |
|
$916,769 |
|
$761,561 |
Net
Income Available to Class C Common
Stockholders |
|
$338,974 |
|
$313,266 |
|
$260,230 |
Basic
Net Income Per Common Share Available to Common
Stockholders |
|
$3.16 |
|
$2.98 |
|
$2.43 |
Diluted Net Income Per Common Share Available to
Common Stockholders |
|
$3.10 |
|
$2.92 |
|
$2.38 |
Basic
and Diluted Income Per Share – Class C
Common |
|
$0.89 |
|
$0.82 |
|
$0.68 |
Weighted Average Basic Shares Outstanding –
Common Stockholders |
|
6,287,510 |
|
6,161,599 |
|
6,050,893 |
Weighted Average Diluted Shares Outstanding –
Common Stockholders |
|
6,415,014 |
|
6,289,103 |
|
6,178,397 |
Weighted Average Basic and Diluted Shares
Outstanding – Class C Common |
|
382,513 |
|
382,513 |
|
382,513 |
Contact: Daniel Culver
Director of Communications
E-mail: investor@fonar.com
www.fonar.com
The Inventor of MR Scanning™
An ISO 9001 Company
Melville, New York 11747
Phone: (631) 694-2929
Fax: (631) 390-1772
Fonar (NASDAQ:FONR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fonar (NASDAQ:FONR)
Historical Stock Chart
From Apr 2023 to Apr 2024